Apyx Medical reshuffles board committees after Executive Chairman appointment

Board committees, the subgroups of directors responsible for a company's audit, compensation, governance, and regulatory compliance oversight, got new chairs and members at Apyx Medical Corporation (Nasdaq: APYX) on July 24, 2026. The Clearwater, Florida medical device maker disclosed the changes in a Form 8-K filed the same day. Three independent directors now divide chair duties across four standing committees, a lineup shaped partly because the company's newly appointed Executive Chairman stepped away from all committee seats.

How the four committees now break down

The Audit Committee will be chaired by Lawrence J. Waldman, joined by Minnie Baylor-Henry and Wendy Levine. Waldman also carries the SEC designation of "audit committee financial expert," a formal label for directors with enough accounting or financial management experience to read and evaluate a company's reported financials without relying exclusively on outside auditors.

Baylor-Henry takes the chair on two bodies: the Governance and Nominating Committee and the Regulatory Compliance Committee. Both carry the same three-person roster of Baylor-Henry, Waldman, and Levine. On the Compensation Committee, Levine holds the chair with Waldman and Baylor-Henry as members.

Why the executive chair seat stays off these committees

The reconstitution follows a leadership change. Stavros Vizirgianakis became Executive Chairman of the Board effective June 11, 2026. Because that is an executive role rather than an independent one, Vizirgianakis will not sit on any of the four committees going forward.

Board independence is a Nasdaq listing requirement. The exchange's rules mandate that certain committees, particularly audit and compensation, be composed entirely of directors with no material financial relationship to the company that could affect their judgment. Apyx Medical's board formally determined that Waldman, Baylor-Henry, and Levine each meet that standard under both Nasdaq and SEC rules.

What this filing covers and what it does not

The 8-K describes a governance reorganization, nothing more. No financial figures, product updates, or revenue guidance appear in the document. Matthew Hill, Apyx Medical's Chief Financial Officer, Secretary and Treasurer, signed the filing on behalf of the company.

The practical result is a formal separation between the executive function Vizirgianakis now holds and the independent board oversight that Waldman, Baylor-Henry, and Levine will each carry across multiple committee roles.